European Union - English - EMA (European Medicines Agency)

pfizer ltd. - sitaxentan sodium - hypertension, pulmonary - antihypertensives, - treatment of patients with pulmonary arterial hypertension (pah) classified as who functional class iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - sitaxentan sodium - tablet - 100mg

Canada - English - Health Canada

pfizer canada ulc - sitaxsentan sodium - tablet - 100mg - sitaxsentan sodium 100mg - miscellaneous vasodilatating agents

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - warfarin sodium - tablet - 1 mg - warfarin sodium 1 mg

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - warfarin sodium - tablet - 3 mg - warfarin sodium 3 mg

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - warfarin sodium - tablet - 5 mg - warfarin sodium 5 mg

United States - English - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - rifapentine (unii: xjm390a33u) (rifapentine - unii:xjm390a33u) - rifapentine 150 mg - priftin® (rifapentine) is indicated in adults and children 12 years and older for the treatment of active pulmonary tuberculosis (tb) caused by mycobacterium tuberculosis . priftin must always be used in combination with one or more antituberculosis (anti-tb) drugs to which the isolate is susceptible [see dosage and administration (2.1) and clinical studies (14.1)] . limitations of use do not use priftin monotherapy in either the initial or the continuation phases of active antituberculous treatment. priftin should not be used once weekly in the continuation phase regimen in combination with isoniazid (inh) in hiv-infected patients with active pulmonary tuberculosis because of a higher rate of failure and/or relapse with rifampin (rif)-resistant organisms [see warnings and precautions (5.4) and clinical studies (14.1)] . priftin has not been studied as part of the initial phase treatment regimen in hiv-infected patients with active pulmonary tuberculosis. priftin is indicated in adults and children 2 years

United States - English - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - rifapentine (unii: xjm390a33u) (rifapentine - unii:xjm390a33u) - rifapentine 150 mg - priftin® (rifapentine) is indicated in adults and children 12 years and older for the treatment of active pulmonary tuberculosis (tb) caused by mycobacterium tuberculosis . priftin must always be used in combination with one or more antituberculosis (anti-tb) drugs to which the isolate is susceptible [see dosage and administration (2.1) and clinical studies (14.1)]. limitations of use do not use priftin monotherapy in either the initial or the continuation phases of active antituberculous treatment. priftin should not be used once weekly in the continuation phase regimen in combination with isoniazid (inh) in hiv-infected patients with active pulmonary tuberculosis because of a higher rate of failure and/or relapse with rifampin (rif)-resistant organisms [see warnings and precautions (5.4) and clinical studies (14.1)]. priftin has not been studied as part of the initial phase treatment regimen in hiv-infected patients with active pulmonary tuberculosis. priftin is indicated in adults and children 2 years an

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

macleods pharmaceuticals limited, india - rifapentine   - film coated tablet - 300mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

macleods pharmaceuticals limited, india - rifapentine , isoniazid tablets 300 mg/300mg - film coated tablets - 300/300